WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004006931) PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/006931    International Application No.:    PCT/IB2003/003098
Publication Date: 22.01.2004 International Filing Date: 07.07.2003
Chapter 2 Demand Filed:    28.08.2003    
IPC:
A61K 31/519 (2006.01), A61K 45/06 (2006.01)
Applicants: WARNER-LAMBERT COMPANY LLC [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US) (For All Designated States Except US).
ROARK, William, Howard [US/US]; (US) (For US Only)
Inventors: ROARK, William, Howard; (US)
Agent: LUMB, J., Trevor; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US)
Priority Data:
60/396,785 17.07.2002 US
Title (EN) PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2
(FR) COMBINAISON D'UN INHIBITEUR ALLOSTERIQUE CARBOXYLIQUE DE LA METALLOPROTEINASE MATRICIELLE 13 AVEC UN INHIBITEUR SELECTIF DE LA CYCLOOXYGENASE-2 QUI N'EST PAS UN CELECOXIB OU UN VALDECOXIB
Abstract: front page image
(EN)This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib and their use for the treatment of diseases that are responsive to inhibition of MMP.13 and cyclooxygenase-2.
(FR)L'invention concerne une combinaison comprenant un inhibiteur allostérique carboxylique de la MMP-13 ou un sel de celle-ci pharmaceutiquement acceptable avec un inhibiteur sélectif de la COX-2 ou un sel de celle-ci pharmaceutiquement acceptable qui n'est pas un Celecoxib ou un Valdecoxib; et son utilisation pour traiter des maladies sensibles à l'inhibition de la MMP-13 et de la cyclooxygénase-2.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)